Xin Lang Cai Jing·2025-09-12 05:26Group 1 - The core viewpoint of the news is that CanSino's stock has experienced fluctuations, with a current price of 83.06 CNY per share and a market capitalization of 20.55 billion CNY, reflecting a year-to-date increase of 36.05% [1] - As of June 30, CanSino had 17,500 shareholders, a decrease of 1.92% from the previous period, with an average of 0 circulating shares per shareholder [2] - For the first half of 2025, CanSino reported a revenue of 382 million CNY, representing a year-on-year growth of 26%, while the net profit attributable to shareholders was -13.49 million CNY, showing a significant increase in losses of 94.02% [2] Group 2 - CanSino's main business involves the research, production, and commercialization of innovative vaccines, with vaccine sales accounting for 97.84% of total revenue [1] - The company has cumulatively distributed 198 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3] - CanSino operates within the pharmaceutical and biotechnology industry, specifically in the vaccine sector, and is associated with concepts such as monkeypox, anti-influenza, and biopharmaceuticals [1]